Is biotech billionaire Kirk's Intrexon worth $1.4B?

Intrexon has set terms for a proposed $125 million IPO that could value the company at $1.4 billion, providing one of the latest indications of bullish evaluations for the biotech startups going public this year. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.